fig1

Figure 1. Current landscape. Current metastatic urothelial carcinoma (mUC) treatment landscape. Clinical factors which influence treatment selection, such as cisplatin-eligibility, are highlighted in green. Biomarkers are highlighted in yellow. Treatment options are shown in blue. In the second line, erdafitinib is an FDA-approved option but results from the phase III THOR trial (NCT03390504) comparing it against pembrolizumab are not yet available, thus it is shown with a dotted outline. PD-L1: Programmed death-ligand 1; ICI: immune checkpoint inhibitor; 1L: first-line; 2L: second-line; 3L: third-line.